Shivaprasad C, Kalra Sanjay
Department of Endocrinology, M. S. Ramaiah Hospital, Bangalore, India.
Indian J Endocrinol Metab. 2011 Jul;15(Suppl 1):S17-24. doi: 10.4103/2230-8210.83058.
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased plasma glucose, free fatty acids, and triglycerides in insulin-resistant patients. Randomized controlled trials have shown that bromocriptine-QR lowers glycated hemoglobin by 0.4 - 0.8% either as monotherapy or in combination with other anti-diabetes medications. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease, and apart from nausea, the drug is well-tolerated. The novel mechanism of action, good side effect profile, and its effects to reduce cardiovascular event rates make it an attractive option for the treatment of type 2 diabetes.
甲磺酸溴隐亭速释片于2009年5月获美国食品药品监督管理局（FDA）批准，用于治疗2型糖尿病。溴隐亭被认为作用于下丘脑的昼夜神经元活动，以重置胰岛素抵抗患者中异常升高的下丘脑驱动，从而增加血浆葡萄糖、游离脂肪酸和甘油三酯。随机对照试验表明，溴隐亭速释片作为单一疗法或与其他抗糖尿病药物联合使用时，可使糖化血红蛋白降低0.4 - 0.8%。用于治疗糖尿病的剂量（每日高达4.8毫克）远低于用于治疗帕金森病的剂量，并且除恶心外，该药物耐受性良好。其新颖的作用机制、良好的副作用 profile 以及降低心血管事件发生率的作用，使其成为治疗2型糖尿病的一个有吸引力的选择。 （注：这里“profile”不太明确准确意思，结合语境大致如此翻译）
